Enhertu Approved for Any HER2-Positive Solid Cancer - NCI
WEBMay 3, 2024 · The drug trastuzumab deruxtecan (Enhertu) can now be used to treat a wide variety of cancers, thanks to a new approval from the Food and Drug Administration (FDA).
Enhertu demonstrated clinically meaningful survival across …
WEBOct 23, 2023 · AstraZeneca and Daiichi Sankyo’s Enhertu showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population
Enhertu Dramatically More Effective Than Kadcyla as Second …
WEBEnhertu more than doubled the 12-month progression-free survival rate than Kadcyla in people with metastatic HER2-positive breast cancer that had been treated.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the …
WEBApr 5, 2024 · AstraZeneca and Daiichi Sankyo's ENHERTU ® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.
ENHERTU - Business Wire
WEB6 days ago · A post-hoc analysis in patients with active brain metastases showed the CNS ORR was 82.6% (n=19/23) for patients who had not received prior local CNS therapy and 50.0% (n=19/38) in patients who ...
Enhertu granted Priority Review in the US for patients ... - AstraZeneca
WEBJan 29, 2024 · AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumours who have received prior treatment or who ...
Enhertu Effective in HER2-Positive Metastatic Breast Cancer
WEBOct 19, 2021 · In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show.
Enhertu demonstrated a median progression-free survival of 13.2 …
WEBJun 2, 2024 · With Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and HER2-low metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings.
FDA approves new treatment option for patients with HER2 …
WEBFDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received two or more...
ENHERTU® Granted Priority Review in the U.S. for Patients with ...
WEBJan 29, 2024 · Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid ...